达美康缓释片联合诺和锐30治疗2型糖尿病初步研究.docVIP

达美康缓释片联合诺和锐30治疗2型糖尿病初步研究 　　【摘要】 目的 探讨达美康缓释片联合诺和锐30对2型糖尿病的治疗效果。方法 将入选患者随机分成达美康缓释片加诺和锐30治疗组和二甲双胍联合诺和灵30R对照组,疗程为6个月,药物治疗前和治疗后1、3、6月末抽静脉血查空腹血糖(FBG)、餐后2 h血糖(PG2 h)、糖化血红蛋白(HbA1c)、TG、TC、C-P及餐后2 hC-P(C-P2 h)。结果 两组治疗前后对比差异均有统计学意义,两组治疗下降值对比除餐后2 h血糖外其余差异无统计学意义。结论 对于非重度肥胖2型糖尿病患者口服降糖药物疗效欠佳或初发糖尿病患者空腹血糖较高时可以选用达美康缓释片加诺和锐30治疗。 　　【关键词】糖尿病 2型; 格列齐特; 二甲双胍; 诺和锐30; 诺和灵30R 　　Preliminary study of type 2 diabetes,treatment with gliclazide sustained-release tablets and aspart 30 　　【Abstract】 Objective To explore the therapy of gliclazide sustained-release tablets and aspart 30 to cure type 2 diabetes patients.Methods Selected patients were randomly divided into gliclazide sustained-release tablets(+aspart 30)treatment group and metformin(+Novolin 30R)control group, the course of treatment 6 monthsThe baseline fasting blood glucose,2-hour postprandial blood glucose,glycosylated hemoglobin,total cholesterol,triglyceride,fasting serum C-P and 2-hour postprandial serum C-P were inspected.Results In the two groups before and after treatment,differences was statistically significant in fasting blood glucose,2-hour postprandial blood glucose,glycosylated hemoglobin,total cholesterol,triglyceride,fasting serum C-P and 2-hour postprandial serum C-P.At the same time changes were not statistically significant between the two groups,except in 2-hour postprandial blood glucose.Conclusion Patients can be treated with gliclazide sustained-release tablets and aspart 30 for non-severely obese type 2 diabetic patients when the treat with oral hypoglycemic drug is ineffective for initial onset diabetes with the fasting blood glucose is high. 　　【Key words】Diabetes mellitustype 2; Gliclazide; Metformin; Aspart 30; Novolin 30R 　　 　　2型糖尿病患者,随着治疗时间的延长,可能出现联合两种甚至三种口服降糖药物治疗后,血糖仍然控制不理想,此时往往需要用胰岛素以补充或替代治疗。有时新诊断糖尿病患者血糖较高,单用口服药物可能疗效欠佳,也往往需要加用胰岛素治疗。其中,使用口服降糖药物加用预混胰岛素早晚餐前注射是一种应用较为广泛的治疗方案。近年来,胰岛素类似物的研制成功及临床应用,为糖尿病的治疗提供了新的选择。研究表明,与诺和灵30R相比,诺和锐30在餐后血糖控制及低血糖发生率方面更具优势。达美康缓释片是格列齐特的缓释剂型,现有资料显示其在血糖控制及患者依从性方面较普通剂型更好。本文旨在初步探